EUVIMEDEUVIMED entdecken
Crossref

A Mitochondria-Targeted CPI-613 Derivative Overcomes Gemcitabine Resistance and Reduces Hepatic Metastasis in Pancreatic Cancer

Min Yang, Jiaming Ou, Hong Yang, Mingyang Xu, Zhenzhen Dai, Haibo Yan, Linling Gan, Yun He, Shao-Lin Zhang

Journal of Medicinal Chemistry · 20.11.2026

DOI: 10.1021/acs.jmedchem.6c02810 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.11.2026. Verfasst von Min Yang und 8 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Chongqing Municipal Education Commission, Graduate School, Chongqing University, Natural Science Foundation of Chongqing Municipality.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) can acquire an oxidative phosphorylation (OXPHOS)-high phenotype, creating a therapeutically exploitable vulnerability. Here, we developed compound 17, a triphenylphosphonium-conjugated CPI-613 derivative that suppresses pyruvate dehydrogenase complex (PDC) activity and mitochondrial respiration. By perturbing oxidative metabolism and redox homeostasis, 17 induced mitochondrial dysfunction and ferroptotic cell death, with PANC-1-GemR cells displaying greater sensitivity than parental PANC-1 cells. This selectivity translated in vivo: 17 outperformed gemcitabine in resistant xenografts and dose-dependently suppressed syngeneic Panc02 tumors. Compound 17 also attenuated EMT-associated phenotypes and hepatic metastatic burden without overt toxicity. These findings identify OXPHOS dependence as an actionable vulnerability in drug-resistant PDAC and position 17 as a promising mitochondria-targeted candidate for treating PDAC and limiting hepatic metastasis.

Förderung

  • Chongqing Municipal Education Commission
  • Graduate School, Chongqing University
  • Natural Science Foundation of Chongqing Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Yang, M., Ou, J., Yang, H., Xu, M., Dai, Z., Yan, H., Gan, L., He, Y., & Zhang, S. (2026). A Mitochondria-Targeted CPI-613 Derivative Overcomes Gemcitabine Resistance and Reduces Hepatic Metastasis in Pancreatic Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02810

Vancouver

Yang M, Ou J, Yang H, Xu M, Dai Z, Yan H, et al. A Mitochondria-Targeted CPI-613 Derivative Overcomes Gemcitabine Resistance and Reduces Hepatic Metastasis in Pancreatic Cancer. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02810

BibTeX
@article{Yang2026,
  author = {Yang, Min and Ou, Jiaming and Yang, Hong and Xu, Mingyang and Dai, Zhenzhen and Yan, Haibo and Gan, Linling and He, Yun and Zhang, Shao-Lin},
  title = {A Mitochondria-Targeted CPI-613 Derivative Overcomes Gemcitabine Resistance and Reduces Hepatic Metastasis in Pancreatic Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02810}
}
Kostenlos starten →